STOCK TITAN

InspireMD Announces Talks Featuring CGuard and CGuard Prime at VEITHsymposium 2026

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

InspireMD (Nasdaq: NSPR) announced talks featuring CGuard and CGuard Prime at VEITHsymposium, held November 17–21, 2026, in New York City. Two presentations are scheduled for November 20 in Session 86. Piotr Musialek will discuss updated clinical trials, including three-year follow-up data involving 621 asymptomatic patients from the CGUARDIANS trial. Patrick J. Geraghty will present primary endpoint results from C-GUARDIANS II and an update on the ongoing C-GUARDIANS III trial of the SwicthGuard neuroprotection system. No clinical outcome figures were disclosed.

Loading...
Loading translation...

Key Figures

Follow-up cohort: 621 asymptomatic patients
Follow-up cohort
621 asymptomatic patients
Three-year follow-up data from the CGUARDIANS trial to be highlighted

Key Terms

primary endpoint
1 terms
primary endpoint medical
"Primary Endpoint Results of the InspireMD C-GUARDIANS II MICROMESH STENT TCAR Trial"
The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

MIAMI, Nov. 16, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that multiple talks featuring CGuard® and the CGuard Prime carotid stent platform are scheduled to take place at VEITHsymposium 2026, being held November 17–21, 2026, in New York City.

The talks will highlight primary endpoint results from the C-GUARDIANS II trial and the status of the ongoing C-GUARDIANS III trial of the SwicthGuard neuroprotection system (“NPS”) and three-year follow-up data involving 621 asymptomatic patients from the CGUARDIANS trial, among other sessions on the benefits of the CGuard Stent.

Details of the talks are as follows:

Title: Progress And Updated Clinical Trials with the CGuard And CGuard Prime MicroMesh Covered Stents (From InspireMD) Including 3-Year Follow-Up Data On 621 Asymptomatic Patients: Are These MCSTs Making a Positive Difference Without Downsides: Should They Become First Line Therapy for All CAS And TCAR Procedures
Presenter: Piotr Musialek, MD, DPhil, Professor of Cardiovascular Medicine at Jagiellonian University Medical College and St. John Paul II Hospital, Krakow, Poland
Date: Friday, November 20, 2026
Time: 8:06–8:11 a.m. ET
Session: 86

Title: Primary Endpoint Results of the InspireMD C-GUARDIANS II MICROMESH STENT TCAR Trial, And Update On C-GUARDIANS III Trial Status: Will This System Optimize Carotid Stenting
Presenter: Patrick J. Geraghty, MD, Professor of Surgery and Radiology at Washington University School of Medicine in St. Louis, Missouri
Date: Friday, November 20, 2026
Time: 8:12–8:17 a.m. ET
Session: 86

For additional information, visit www.veithsymposium.org.

About VEITHsymposium
VEITHsymposium provides vascular surgeons, interventional radiologists, interventional cardiologists and other vascular specialists with a unique and exciting format to learn the most current information about what is new and important in the treatment of vascular disease. The five-day event features rapid-fire presentations from world-renowned vascular specialists, with emphasis on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

Investor Contacts:
Jeff Warren
LifeSci Advisors
jwarren@lifesciadvisors.com
investor-relations@inspiremd.com


Keep reading